185 related articles for article (PubMed ID: 33465289)
1. The tyrosine kinase v-Src modifies cytotoxicities of anticancer drugs targeting cell division.
Yuki R; Hagino M; Ueno S; Kuga T; Saito Y; Fukumoto Y; Yamaguchi N; Yamaguchi N; Nakayama Y
J Cell Mol Med; 2021 Feb; 25(3):1677-1687. PubMed ID: 33465289
[TBL] [Abstract][Full Text] [Related]
2. The tyrosine kinase v-Src causes mitotic slippage by phosphorylating an inhibitory tyrosine residue of Cdk1.
Horiuchi M; Kuga T; Saito Y; Nagano M; Adachi J; Tomonaga T; Yamaguchi N; Nakayama Y
J Biol Chem; 2018 Oct; 293(40):15524-15537. PubMed ID: 30135207
[TBL] [Abstract][Full Text] [Related]
3. Preferential Killing of Tetraploid Colon Cancer Cells by Targeting the Mitotic Kinase PLK1.
Jemaà M; Kifagi C; Serrano SS; Massoumi R
Cell Physiol Biochem; 2020 Apr; 54(2):303-320. PubMed ID: 32259417
[TBL] [Abstract][Full Text] [Related]
4. Mitotic arrest and slippage induced by pharmacological inhibition of Polo-like kinase 1.
Raab M; Krämer A; Hehlgans S; Sanhaji M; Kurunci-Csacsko E; Dötsch C; Bug G; Ottmann O; Becker S; Pachl F; Kuster B; Strebhardt K
Mol Oncol; 2015 Jan; 9(1):140-54. PubMed ID: 25169932
[TBL] [Abstract][Full Text] [Related]
5. Co-inhibition of polo-like kinase 1 and Aurora kinases promotes mitotic catastrophe.
Li J; Hong MJ; Chow JP; Man WY; Mak JP; Ma HT; Poon RY
Oncotarget; 2015 Apr; 6(11):9327-40. PubMed ID: 25871386
[TBL] [Abstract][Full Text] [Related]
6. Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma.
Stehle A; Hugle M; Fulda S
Cancer Lett; 2015 Aug; 365(1):37-46. PubMed ID: 25917079
[TBL] [Abstract][Full Text] [Related]
7. Modeling the mitotic regulatory network identifies highly efficient anti-cancer drug combinations.
Wu Y; Zhuo X; Dai Z; Guo X; Wang Y; Zhang C; Lai L
Mol Biosyst; 2015 Feb; 11(2):497-505. PubMed ID: 25418836
[TBL] [Abstract][Full Text] [Related]
8. Loss of p21Cip1/CDKN1A renders cancer cells susceptible to Polo-like kinase 1 inhibition.
Kreis NN; Louwen F; Zimmer B; Yuan J
Oncotarget; 2015 Mar; 6(9):6611-26. PubMed ID: 25483104
[TBL] [Abstract][Full Text] [Related]
9. Tubulin-binding agents down-regulate matrix metalloproteinase-2 and -9 in human hormone-refractory prostate cancer cells – a critical role of Cdk1 in mitotic entry.
Chang WL; Yu CC; Chen CS; Guh JH
Biochem Pharmacol; 2015 Mar; 94(1):12-21. PubMed ID: 25615907
[TBL] [Abstract][Full Text] [Related]
10. Tubulin-associated drug targets: Aurora kinases, Polo-like kinases, and others.
Warner SL; Gray PJ; Von Hoff DD
Semin Oncol; 2006 Aug; 33(4):436-48. PubMed ID: 16890798
[TBL] [Abstract][Full Text] [Related]
11. Plk1 inhibition causes post-mitotic DNA damage and senescence in a range of human tumor cell lines.
Driscoll DL; Chakravarty A; Bowman D; Shinde V; Lasky K; Shi J; Vos T; Stringer B; Amidon B; D'Amore N; Hyer ML
PLoS One; 2014; 9(11):e111060. PubMed ID: 25365521
[TBL] [Abstract][Full Text] [Related]
12. Non-mitotic functions of polo-like kinases in cancer cells.
Raab CA; Raab M; Becker S; Strebhardt K
Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188467. PubMed ID: 33171265
[TBL] [Abstract][Full Text] [Related]
13. Biological impact of freezing Plk1 in its inactive conformation in cancer cells.
Keppner S; Proschak E; Kaufmann M; Strebhardt K; Schneider G; Spänkuch B
Cell Cycle; 2010 Feb; 9(4):761-73. PubMed ID: 20139717
[TBL] [Abstract][Full Text] [Related]
14. v-Src-induced nuclear localization of YAP is involved in multipolar spindle formation in tetraploid cells.
Kakae K; Ikeuchi M; Kuga T; Saito Y; Yamaguchi N; Nakayama Y
Cell Signal; 2017 Jan; 30():19-29. PubMed ID: 27871934
[TBL] [Abstract][Full Text] [Related]
15. Blocking Mitotic Exit of Ovarian Cancer Cells by Pharmaceutical Inhibition of the Anaphase-Promoting Complex Reduces Chromosomal Instability.
Raab M; Sanhaji M; Zhou S; Rödel F; El-Balat A; Becker S; Strebhardt K
Neoplasia; 2019 Apr; 21(4):363-375. PubMed ID: 30851646
[TBL] [Abstract][Full Text] [Related]
16. Anti-mitotic therapies in cancer.
Tischer J; Gergely F
J Cell Biol; 2019 Jan; 218(1):10-11. PubMed ID: 30545842
[TBL] [Abstract][Full Text] [Related]
17. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1.
Lénárt P; Petronczki M; Steegmaier M; Di Fiore B; Lipp JJ; Hoffmann M; Rettig WJ; Kraut N; Peters JM
Curr Biol; 2007 Feb; 17(4):304-15. PubMed ID: 17291761
[TBL] [Abstract][Full Text] [Related]
18. Polo and Aurora kinases: lessons derived from chemical biology.
Taylor S; Peters JM
Curr Opin Cell Biol; 2008 Feb; 20(1):77-84. PubMed ID: 18249108
[TBL] [Abstract][Full Text] [Related]
19. The SH3 domain directs acto-myosin-dependent targeting of v-Src to focal adhesions via phosphatidylinositol 3-kinase.
Fincham VJ; Brunton VG; Frame MC
Mol Cell Biol; 2000 Sep; 20(17):6518-36. PubMed ID: 10938128
[TBL] [Abstract][Full Text] [Related]
20. The vanillin derivative 6-bromine-5-hydroxy-4-methoxybenzaldehyde induces aberrant mitotic progression and enhances radio-sensitivity accompanying suppression the expression of PLK1 in esophageal squamous cell carcinoma.
Gu MM; Li M; Gao D; Liu LH; Lang Y; Yang SM; Ou H; Huang B; Zhou PK; Shang ZF
Toxicol Appl Pharmacol; 2018 Jun; 348():76-84. PubMed ID: 29679654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
